Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, et al.
Cancer Discovery (2021) Vol. 12, Iss. 3, pp. 644-653
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel, Megan Othus, Yuanbin Chen, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 9, pp. 813-823
Open Access | Times Cited: 506
Cutaneous melanoma
Georgina V. Long, Susan M. Swetter, Alexander M. Menzies, et al.
The Lancet (2023) Vol. 402, Iss. 10400, pp. 485-502
Closed Access | Times Cited: 323
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 3, pp. 517-527
Open Access | Times Cited: 116
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
NEJM Evidence (2022) Vol. 1, Iss. 11
Closed Access | Times Cited: 105
Systemic Therapy for Melanoma: ASCO Guideline Update
Rahul Seth, Sanjiv S. Agarwala, Hans Messersmith, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 30, pp. 4794-4820
Open Access | Times Cited: 90
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114327-114327
Closed Access | Times Cited: 21
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
Rachel Goodman, Aleigha Lawless, Rachel Woodford, et al.
JAMA Network Open (2023) Vol. 6, Iss. 8, pp. e2327145-e2327145
Open Access | Times Cited: 36
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Teresa Amaral, Margaret Ottaviano, Ana Arance, et al.
Annals of Oncology (2024) Vol. 36, Iss. 1, pp. 10-30
Closed Access | Times Cited: 12
Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
Nina B. Curkovic, Kun Bai, Fei Ye, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 340-340
Open Access | Times Cited: 10
Adjuvant Systemic Immunotherapies for Resected Stage III Melanoma: A Single-Centre Retrospective Clinical Practice Review
Alicia Y Lefas, Çiğdem Çınar, Sreeja Sreekumar, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 750-750
Open Access | Times Cited: 1
Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?
K Sugiyama, Anderley Gordon, Sanjay Popat, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104122-104122
Closed Access | Times Cited: 1
Anatomic Region of Cutaneous Melanoma Impacts Survival and Clinical Outcomes: A Population-Based Analysis
Christian M. Shannon, Neil K. Mehta, Hong Li, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1229-1229
Open Access | Times Cited: 17
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study
Xue Bai, Aleigha Lawless, Juliane A. Czapla, et al.
JAAD International (2024) Vol. 15, pp. 105-114
Open Access | Times Cited: 8
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Mahesh Koirala, Mario DiPaola
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1801-1801
Open Access | Times Cited: 8
Exosome-based immunotherapy as an innovative therapeutic approach in melanoma
Shabnam Babaei, Manouchehr Fadaee, Hajar Abbasi‐Kenarsari, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?
Christopher D. Lao, Nikhil I. Khushalani, Christina V. Angeles, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 738-744
Open Access | Times Cited: 25
Advances in targeted therapy and immunotherapy for melanoma (Review)
Ziyao Qin, Mei Zheng
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 16
Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
Hildur Helgadóttir, Lars Ny, Gustav Ullenhag, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 9, pp. 1077-1084
Open Access | Times Cited: 14
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Xue Bai, Shaheen Ahmed, Charlotte Grieco, et al.
EClinicalMedicine (2023) Vol. 65, pp. 102290-102290
Open Access | Times Cited: 14
Adjuvant immunotherapy for melanoma patients: progress and opportunities
Tamara A. Sussman, Patrick A. Ott
ESMO Open (2024) Vol. 9, Iss. 5, pp. 102962-102962
Open Access | Times Cited: 5
Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations
Walid Shalata, Zoé Gabrielle Attal, Adam Solomon, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5794-5794
Open Access | Times Cited: 5
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma
Hacı Arak, Suna Erkılıç, Şendağ Yaslıkaya, et al.
Journal of Immunotherapy (2024) Vol. 47, Iss. 5, pp. 182-189
Open Access | Times Cited: 4
Access to melanoma drugs in Spain: a cross-sectional survey
María González‐Cao, Teresa Puértolas, José Luís Manzano, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 10, pp. 2572-2583
Closed Access | Times Cited: 4
Optimal systemic therapy for high-risk resectable melanoma
Alexander M.M. Eggermont, Omid Hamid, Georgina V. Long, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 7, pp. 431-439
Closed Access | Times Cited: 18
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges
Sowmya Cheruvu, David McMahon, James Larkin
Expert Opinion on Biological Therapy (2025), pp. 1-12
Closed Access
Page 1 - Next Page

Scroll to top